copenhagen denmark, January 9, 2023 /PR Newswire/ — Novo Holdings, a leading international life sciences investment company, today announced $40 million Investment in Evosep, a bioscience company leading the standardization of clinical proteomics.
Proceeds from Novo Holdings’ investment will be used to advance clinical applications of proteomics enabled by Evosep’s standardized liquid chromatography platform. The new funding will also enable Evosep to further expand its presence globally, particularly in the fast-growing US market, to offer robust, high-throughput proteomics solutions to a wider range of customers.
Evosep was founded in 2016 by pioneers in proteomics technology. take shape, along with some of Evosep’s senior leaders, all of whom have a long history of working together in the field of liquid chromatography-mass spectrometry (LC-MS). Team unlocks the power of LC-MS for drug discovery and improves quality of life and patient care by innovating how protein-based clinical diagnostics are performed across panels using multiple protein biomarkers He founded Evosep with a mission to Existing high-throughput solutions tend to rely on single protein assays.
Since 2016, the team has commercialized best-in-class liquid chromatography platforms with ease-of-use and robustness, with industry-leading customer satisfaction and results that have been very well received by both the scientific and pharmaceutical communities. I am profiting. Evosep has strong partnerships and instrument compatibility across mass spec vendors and instruments.
Evosep is a leading platform that offers high sample throughput capabilities with excellent reproducibility (i.e., valuable and useful data) between sample runs and between instruments and sites. Evosep’s technology shapes the promise of proteomics by developing useful applications, enabling widespread use, and developing clinically relevant protein-based diagnostics.
Stephen Van Heldenmain, Novo HoldingsSaid:
“Evosep’s technology has the potential to significantly impact the diagnosis and treatment of disease. I will deal with it.”
Considering the investment, Steven, based in San Francisco, will join Evosep’s Board of Directors. Stephen adds: In front of you. “
Evosep’s core nano-LC industry is estimated to grow rapidly over the next five years, with increasing global awareness of precision medicine, where medical interventions take patient genetics or protein data into account in diagnosis or treatment. increase. In addition, the clinical diagnosis is >$50 billion The industry, and the development of leading multi-biomarker assays here, will bring substantial benefits to patients and greatly improve available therapeutic pathways.
Christian RavensborgCEO, Evosep said:
“We are pleased to welcome Novo Holdings A/S as a new shareholder of Evosep. Novo Holdings is a well-known company with expertise in working with innovative life sciences companies to unlock their potential. A highly regarded long-term investor, the combined experience will allow the investment to accelerate already strong growth and further expand the platform towards proteomics in bedside care.
Danish Export and Investment Fund is one of the existing investors and has been investing in Evosep since 2016.
Toni Bülow-Nielsen, Partner Danish The Export Investment Fund said:
“Evosep has already proven its potential to become a world leader in proteomics and I have great confidence in the team. Danish a unique position within health tech, and Danish Export and Investment Fund is pleased to partner with Novo Holdings to continue its journey with Evosep. We are confident that Evosep’s advanced technology will make a big positive difference in the healthcare sector. ”
About Novo Holdings A/S
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, one of the world’s largest corporate foundations. Novo Holdings’ aim is to improve human health and social and planetary sustainability by generating attractive long-term returns on the assets of the Novo Nordisk Foundation.
Novo Holdings, wholly owned by the Novo Nordisk Foundation, is the controlling shareholder of Novo Nordisk and Novozymes (a Novo group of companies) and manages investment portfolios with long-term return prospects. Novo Holdings invests in life sciences companies at all stages of development and also manages a broad portfolio of equity, fixed income, real estate, infrastructure assets and private equity investments.
As of the end of 2021, Novo Holdings’ total assets are US$106 billionMore information: www.novoholdings.dk.
About the Novo Nordisk Foundation
Founded in Denmark Founded in 1924, the Novo Nordisk Foundation is a charitable corporate foundation. The Foundation’s vision is to improve people’s health and the sustainability of society and the planet. The Foundation’s mission is to advance research and innovation in the prevention and treatment of cardiometabolic and infectious diseases, and to advance knowledge and solutions to support the green transformation of society.
Evosep aims to improve quality of life and patient care by fundamentally reinventing protein-based clinical diagnostics. The first was through collaboration with world-leading scientists on developing new techniques and solutions that make sample separation 100x more robust and 10x faster than today’s alternatives. Information about Evosep is available at www.evosep.com.
The Evosep One instrument is for Research Only (RUO).
View original content: https://www.prnewswire.com/news-releases/novo-holdings-invests-in-proteomics-technology-company-evosep-301715602.html
SOURCE Novo Holdings